Study #2017-0099
Randomized Embolization Trial for Neuroendocrine Tumor Metastases to the Liver (RETNET): A Phase 2 Randomized Multicenter Trial to Compare Hepatic Progression-Free Survival following Bland Embolization, Lipiodol Chemoembolization, and Drug-Eluting Bead Ch
MD Anderson Study Status
Not Accepting
Treatment Agent
Combination Product: Transarterial chemoembolization, Combination Product: Drug Eluting Beads Embolization
Description
The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Neuroendocrine Tumor, Malignant, Liver Metastases
Study phase:
Phase II
Physician name:
Rony Avritscher
Department:
Interventional Radiology
For general questions about clinical trials:
1-866-967-2182
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.